39 results about "E2 prostaglandin" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of prostaglandin E2 in preparation of a medicine for treating retina injury caused by blue light exposure. The prostaglandin E2 medicine or the medicine composition is used for preventing or treating retina injury caused by blue light exposure, the medicine or the medicine composition has the functions of relieving shortening of a retina photoreceptor cell layer and relieving decline of retina electrophysiology a waves and b waves, and then pathological changes related to retina diseases can be improved.

The invention belongs to the technical field of biology, and particularly relates to a composition for tumor targeted therapy, hydrogel and a preparation method and application thereof. The tumor targeted therapy composition provided by the invention comprises the aging tumor cells and the celecoxib, the immune activation function of the aging tumor cells is that STCs can effectively activate the maturation of dendritic cells and the immune function of T cells and NK cells, SASP of the STCs is regulated through the celecoxib, especially generation of prostaglandin E2 is inhibited, and the tumor targeted therapy effect is improved. And the combined use further enhances the anti-tumor immune effect.

The invention relates to the technical field of equipment control, and discloses a control method of a wave conduction health care instrument capable of outputting different waveforms based on symptoms, and the method comprises the steps: transmitting a 1-10MHz multi-frequency detection wave to a target treatment area, calculating tissue impedance distribution through a reflected wave, and obtaining a focus boundary coordinate based on an impedance difference threshold; on the basis of the impedance-frequency response curve, an inverse phase compensation waveform is generated through a time reversal algorithm, the inverse phase compensation waveform comprises a phase delay component in negative correlation with the impedance curve, and tissue scattering distortion is counteracted; synchronously starting the electrical stimulation module and the ultrasonic module; the focus coordinates are repeatedly updated every 30 seconds, and the electrical stimulation focusing position is adjusted; the concentration of lactic acid and the concentration of prostaglandin E2 in tissue fluid are detected in real time through a microfluidic sensor, and correction is triggered when any concentration exceeds the limit, specifically, lactic acid ultralimit switching electrical stimulation is 50-100 Hz damped oscillatory waves (larger than or equal to 5 minutes), prostaglandin E2 ultralimit switching ultrasound is in a pulse mode, and the electrical stimulation amplitude is increased. The treatment effect of the waveform treatment equipment can be improved.

The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and / or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising these compounds. The compounds provided herein can be used as prostaglandin E2 (PGE2) EP4 receptor antagonists, which makes them very useful for therapy, particularly for the treatment or prevention of cancer, neovascular eye disease, inflammatory pain or inflammatory diseases such as multiple sclerosis, rheumatoid arthritis or endometriosis. #imgabs0#

The present invention provides a culture medium for primary ovarian cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; epidermal growth factor; gastrin; insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Culturing primary ovarian cancer cells using this culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary ovarian cancer cell culture.

The invention belongs to the technical field of drug delivery and tumor immunotherapy, and particularly relates to an oncolytic virus vesicle as well as a preparation method and application thereof. The preparation method comprises the following steps: co-incubating oncolytic adenovirus and platelets in a buffer system containing prostaglandin E2, and inducing to form an inner membrane encapsulation body; and activating and releasing the vesicles under the conditions of 36-38 DEG C and 4-6% CO2, and carrying out gradient centrifugal collection of 300g, 2000g, 10000g and 100000g. The particle size of the oncolytic virus-loaded vesicle is 50-200nm, the surface of the oncolytic virus-loaded vesicle contains CD41, CD61 and P-selectin, and the oncolytic virus-loaded vesicle can realize long circulation and lung targeting delivery of oncolytic viruses, is suitable for preparing drugs for treating breast cancer and breast cancer lung metastasis, and has a remarkable tumor inhibition effect.

The invention discloses an efficient oxytocic for hippocampus in the late pregnancy period and an oxytocic method of the efficient oxytocic. Research verifies that the odinagogue taking prostaglandin E2 as a main active component can rapidly induce the hippocampus to give birth in the late pregnancy (take effect within 60 minutes after odinagogue), and the odinagogue time is remarkably shortened. The juvenile fish produced by the method has independent viability, has no significant adverse effect on the sea horse with incomplete embryonic development, can effectively improve the mature fry acquisition rate when the embryonic development condition is unknown, reduces the fry loss in the culture process, and is beneficial to sea horse resource protection and industrial layout optimization.

The invention discloses a sleep-aiding pomegranate wine. The pomegranate juice wine is prepared from the following components through three times of gradient fermentation and blending: pomegranate juice primary fermented wine with the volume ratio of 60 + / -2%, the alcoholic strength of 8-9% vol and the fermentation temperature of 1-3 DEG C; the pomegranate rind processing wine has a volume ratio of 10 + / -1%, the pomegranate rind is processed by a traditional Chinese medicine processing technology, and then low-temperature extraction is carried out at an extraction temperature of less than or equal to 50 DEG C; flavonoid compounds (such as quercetin and kaempferol) in pomegranate seeds can inhibit the activity of epoxidase-2 (COX-2) and reduce the release of inflammatory factors such as prostaglandin E2 (PGE2) (experimental data: the inhibition rate is greater than or equal to 65%); vitamin C and polyphenol cooperate to promote joint synovial cells to secrete hyaluronic acid, the viscoelasticity of the joint lubricating fluid is improved (the viscosity is increased by 30%), and the pain of osteoarthritis is relieved.

The present invention relates to the field of pharmaceutical applications, and in particular to a marker for viral pneumonia and its application, wherein the marker for viral pneumonia is prostaglandin E2 and / or prostaglandin M. The present invention uses prostaglandin E2 and / or prostaglandin M as markers for viral pneumonia, and the use of cyclooxygenase II inhibitors can effectively and quickly reduce prostaglandins, reverse the progression of common and severe cases, block the occurrence of critical illness, promote viral conversion to negative, pneumonia absorption and health recovery. The drug will expand its clinical use scope upon further confirmation of its efficacy, incorporate the treatment method into clinical diagnosis and treatment plans, and provide new strategies and diagnosis and treatment methods for the comprehensive treatment of new coronary pneumonia.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

The invention discloses a reagent composition for constructing an acute inflammation model and a construction method. In the invention, local slow release of TNF-alpha is realized through the temperature-sensitive hydrogel, the limitation of traditional systemic administration is broken through, the gradient diffusion characteristic of inflammatory factors in a focus area is restored, and model distortion caused by excessive activation of systemic immune response is avoided. The stepped delivery of the lipopolysaccharide, the prostaglandin E2 analogue and the IL-1beta histamine aerosol effectively covers key pathological links such as vascular permeability change, neutrophil infiltration, oxidative stress and the like through multi-channel synergistic amplification of an inflammation cascade effect. Dynamic balance maintenance of the active oxygen scavenger significantly improves the stability of the model, ensures that the inflammation process is controllable and reversible, provides a reliable window period for drug testing, and real-time fluorescence monitoring and end-point multi-index joint inspection form a closed-loop verification system, so that dynamic migration characteristics of inflammation can be captured, the end damage degree can be quantified, and the accuracy of drug detection is improved. And a complete data link from a process to a result is provided for mechanism research.

The present invention belongs to the field of pharmaceutical technology, and particularly relates to the application of prostaglandin E2 in the preparation of a medicament for treating retinal damage caused by blue light exposure. The present invention uses a prostaglandin E2 medicament or a pharmaceutical composition to prevent or treat retinal damage caused by blue light exposure. The medicament or the pharmaceutical composition has the function of reducing the shortening of the retinal photoreceptor cell layer and alleviating the decline of the electroretinogram a-wave and b-wave, and thus can improve the pathological changes related to retinal diseases.

The invention discloses a retinal organoid culture medium and application thereof, and relates to the field of organoid culture. The culture medium comprises a basic culture medium and specific addition factors, wherein the specific addition factors comprise A8301, Forskolin, Prostaglandin E2, R-Spondin protein, Noggin protein and FGF10 (Fibroblast Growth Factor 10) protein, and the specific addition factors comprise A8301, Forskolin, Prostaglandin E2, R-Spondin protein, Noggin protein and FGF10 (Fibroblast Growth Factor 10) protein. The culture medium disclosed by the invention can be used for obtaining retina organoid culture from retina tissue culture, and is high in organoid formation rate, high in biological consistency, high in research value and wide in application prospect.

The invention relates to the technical field of microorganisms, and particularly discloses lactobacillus acidophilus PIS4 capable of improving dysmenorrhea and application of the lactobacillus acidophilus PIS4. The lactobacillus acidophilus PIS4 is separated from genital tracts of healthy women, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.34554, and the preservation date is May 15, 2025. The lactobacillus acidophilus PIS4 is used for preparing the lactobacillus acidophilus PIS4. The lactobacillus acidophilus strain PIS4 provided by the invention is proved to be capable of inhibiting the gene expression of prostaglandin E synthase 2 (pges-2) and reducing the synthesis of prostaglandin E2 and prostaglandin F2alpha, and has effective relieving and improving effects on primary dysmenorrhea.

The present invention provides a culture medium for primary intestinal cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; insulin; a Rho protein kinase inhibitor selected from at least one of Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; a glutamine additive; neuregulin 1; a bovine pituitary extract; basic fibroblast growth factor; R-spondin 1; prostaglandin E2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher amplification efficiency. Using this culture medium for primary intestinal cancer cells can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary intestinal cancer cell culture.

The present invention relates to a cosmetic composition comprising yeast fermentation or yeast polypeptide and troxerutin as active ingredients. The composition according to the present invention has an excellent inhibitory effect on the expression and production of nitric oxide (NO), interleukin-1 [alpha] (IL-1 [alpha]), interleukin-1 [beta] (IL-1 [beta]), interleukin-8 (IL-8), and prostaglandin E2 (PGE2), and thus can be effectively applied to cosmetics and external medicines for resisting inflammation, improving or preventing sensitive skin, or calming skin, and the like.

A treatment of an immune-related disease and / or an inflammatory process in an individual by administering a cell composition to a patient, the cell composition including isolated mesenchymal stem cells measured positive for mesenchymal markers CD29, CD44 and CD90 and negative for MHC class II molecules, the cell secretes immunomodulatory prostaglandin E2 cytokine when present in an inflammatory environment or condition.

The invention relates to the technical field of cosmetics, in particular to application of a compound Drimendol or a compound Epimendol to preparation of cosmetics. The prepared cosmetic has the effects of moisturizing, repairing, tightening, nourishing, resisting wrinkles and relieving, is mild and non-irritating, is suitable for sensitive skin, has the effects of positively regulating and expressing the acid sphingomyelinase SMPD1 gene and the LOR gene and improving the skin barrier, has the effects of positively regulating and expressing the elastin ELN gene and improving the skin elasticity and compactness, and is suitable for the sensitive skin. The composition has the effects of negative regulation expression of tumor necrosis factor-alpha, interleukin-1alpha and prostaglandin E2 genes, improvement of skin inflammation and relieving of sensitive skin, has negative regulation expression of transient receptor potential vanillin-1 receptor genes, achieves the effects of skin analgesia and anti-inflammation, and has the effect of increasing synthesis of skin cell hyaluronic acid.

The invention belongs to the technical field of pet food, and particularly relates to pet snacks with a joint protection function. The pet snack food is prepared from the following raw materials in parts by weight: 40 to 55 parts of starch, 20 to 25 parts of meat, 15 to 20 parts of rice flour, 5 to 10 parts of pea protein, 4 to 5 parts of glycerol, 1 to 2 parts of fish oil, 0.1 to 0.2 part of potassium sorbate, 0.1 to 0.2 part of calcium propionate, 0.03 to 0.05 part of vitamin C, 0.01 to 0.03 part of rosemary extract, 0.01 to 0.03 part of sunset yellow, 0.01 to 0.03 part of caramel pigment, 0.2 to 0.5 part of eggshell membrane powder, 0.01 to 0.05 part of curcumin and 10 to 20 parts of water. The eggshell membrane powder and curcumin are combined for use, so that the prostaglandin E2 level is remarkably reduced, arthralgia is relieved, articular cartilage repair is promoted, the joint function is improved, and gastrointestinal discomfort, diarrhea and the like of pets cannot be caused.

The invention belongs to the technical field of biomedicine, and relates to a culture medium for human placenta organoid in early pregnancy as well as preparation and application of the culture medium. The culture medium is prepared from DMEM / F12, and an N-2 additive is added into the culture medium; a B-27 additive; primary cell antibiotics; and N, N-acetyl-L-cysteine; l, L-glutamine; recombinant human epidermal growth factors; cHIR99021, CHIR99021; a recombinant human R-spinal protein 1; recombining a human fibroblast growth factor; recombinant human hepatocyte growth factors; a83-01, A83-01; prostaglandin E2; y-27632, Y-27632; and fetal bovine serum albumin. By improving the components of the culture medium of the human placenta organoid, the obtained human placenta organoid is better in growth state and balling rate, the apoptosis of the organoid is reduced, and a foundation is laid for further application to research of downstream molecular biology and cytobiology.

This prostaglandin E2 production inhibitor contains, as an active ingredient, at least one peptide selected from the group consisting of Pro-Hyp, Hyp-Gly, Ala-Hyp-Gly, Pro-Pro, Pro-Gly, and Gly-Pro, or a salt thereof, or a chemically modified product of the peptide or the salt, wherein the total content of the active ingredient(s) is 5000 ppm by mass or more.

The invention discloses a culture medium and a culture method for dedifferentiating liposarcoma organs, the culture medium takes DMEM / F12 as a basic culture medium, and the following components with final concentration are added: 1-5 mM of N-acetylcysteine, 1-20 mM of nicotinamide, 10-30 ng / ml of fibroblast growth factor 2, 1 * B27, 10 [mu] M of Y-27632, 500-1000 ng / ml of R-spondin1, 500-1000 nM of prostaglandin E2, 5-10 [mu] M of SB202190, 1 * HEPES, 1 * GlutaMAX, 1 * P / S, 10-50 nM of hydrocortisone and 5-10% of fetal calf serum; the components of the culture medium interact with one another, in-vitro growth of the dedifferentiated liposarcoma can be promoted under the overall action effect, the dedifferentiated liposarcoma organoid is obtained, and the obtained organoid can be stably cultured and amplified in vitro for a long time.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

The invention belongs to the field of biological medicines, and particularly relates to a novel application of forsythin in preparation of a medicine for preventing and treating amyotrophy. In-vivo and in-vitro experiments prove that the phillyrin can remarkably improve the level of endogenous prostaglandin E2 by inhibiting the activity or expression of 15-hydroxyprostaglandin dehydrogenase in muscular tissues, so that the expression of muscular atrophy key factors FOXO3a and Atrogin-1 is inhibited, and finally the effects of protecting muscle quality and improving muscle functions are achieved. The invention reveals that forsythin has the functions of inhibiting 15-PGDH and relieving muscle atrophy for the first time, and brand new medical application is provided for forsythin. The invention provides a brand-new therapeutic scheme and pharmaceutical composition for treating sarcopenia by using forsythin as an active component and regulating the 15-PGDH / PGE2 pathway. The invention provides an important candidate compound for developing efficient and safe sarcopenia resisting medicines, and has important practical significance.

The invention belongs to the technical field of animal breeding. More specifically, the invention relates to a method for predicting ewe embryo transplantation pregnancy results. The research finds that luteinizing hormone, cortisol and prostaglandin E2 in the estrus period of the ewe have significant correlation with the pregnancy result after the ewe embryo transplantation in a specific concentration range for the first time, and ROC curve analysis proves that the three can be used as biomarkers for predicting the pregnancy result after the ewe embryo transplantation. On the basis, the invention provides a method for predicting the pregnancy result of ewe embryo transplantation, and the pregnancy result is predicted according to the concentration of the reproductive hormone by detecting the concentration of the reproductive hormone in the peripheral blood of the receptor ewe in the estrus period. According to the method, pregnancy potential evaluation can be realized before transplantation, and the prediction timeliness is remarkably improved. In addition, breeding managers can screen high-pregnancy-potential individuals accordingly, and breeding efficiency is improved. The hormone abuse condition in embryo transplantation is reduced, the culture cost is reduced, and the method has good application prospects and value.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.